These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 20684746)

  • 1. Metabolism considerations for kinase inhibitors in cancer treatment.
    Duckett DR; Cameron MD
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1175-93. PubMed ID: 20684746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
    Ding JF; Zhong DF
    Yao Xue Xue Bao; 2013 Jul; 48(7):1080-90. PubMed ID: 24133973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
    Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
    Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
    Brózik A; Hegedüs C; Erdei Z; Hegedus T; Özvegy-Laczka C; Szakács G; Sarkadi B
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):623-42. PubMed ID: 21410427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of tyrosine kinase inhibitors.
    van Erp NP; Gelderblom H; Guchelaar HJ
    Cancer Treat Rev; 2009 Dec; 35(8):692-706. PubMed ID: 19733976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
    Hartmann JT; Haap M; Kopp HG; Lipp HP
    Curr Drug Metab; 2009 Jun; 10(5):470-81. PubMed ID: 19689244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS; Ioannidis GN; Ardavanis AG
    Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S; Brullo C; Musumeci F; Botta M
    Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.
    Deeken JF; Pantanowitz L; Dezube BJ
    Curr Opin Oncol; 2009 Sep; 21(5):445-54. PubMed ID: 19606034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.
    Patras de Campaigno E; Bondon-Guitton E; Laurent G; Montastruc F; Montastruc JL; Lapeyre-Mestre M; Despas F
    Br J Clin Pharmacol; 2017 Jul; 83(7):1544-1555. PubMed ID: 28098949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
    Scheffler M; Di Gion P; Doroshyenko O; Wolf J; Fuhr U
    Clin Pharmacokinet; 2011 Jun; 50(6):371-403. PubMed ID: 21553932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.
    Dai Y
    Expert Opin Ther Pat; 2010 Jul; 20(7):885-97. PubMed ID: 20509775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.
    Beretta GL; Cassinelli G; Pennati M; Zuco V; Gatti L
    Eur J Med Chem; 2017 Dec; 142():271-289. PubMed ID: 28851502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase inhibitors: contributions from structure to clinical compounds.
    Johnson LN
    Q Rev Biophys; 2009 Feb; 42(1):1-40. PubMed ID: 19296866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase blockers: new hope for successful cancer therapy.
    Pytel D; Sliwinski T; Poplawski T; Ferriola D; Majsterek I
    Anticancer Agents Med Chem; 2009 Jan; 9(1):66-76. PubMed ID: 19149483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.
    Haouala A; Widmer N; Duchosal MA; Montemurro M; Buclin T; Decosterd LA
    Blood; 2011 Feb; 117(8):e75-87. PubMed ID: 20810928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.